<SEC-DOCUMENT>0001104659-20-109860.txt : 20200929
<SEC-HEADER>0001104659-20-109860.hdr.sgml : 20200929
<ACCEPTANCE-DATETIME>20200929163657
ACCESSION NUMBER:		0001104659-20-109860
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200929
FILED AS OF DATE:		20200929
DATE AS OF CHANGE:		20200929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		201209298

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2031949d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the month of September 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File
Number 333-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">FORM
20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM 40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant by furnishing
the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- _______</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On September 29, 2020, CureVac N.V. (the &ldquo;Company&rdquo;)
issued a press release announcing that the Company has initiated a Phase 2a clinical trial of its COVID-19 vaccine candidate, CvnCoV.
The dose-confirmation study, CV-NCOV-002, is being conducted in Peru and Panama and is expected to enroll a total of 690 healthy
participants in two groups: older adults ages 61 and above, and younger participants 18 to 60 years old. The press release is attached
hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The information in this Form 6-K (including Exhibit 99.1) shall
not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; vertical-align: top; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; width: 24%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September 29, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; width: 0.9in">EXHIBIT NO.</TD>
    <TD STYLE="padding-bottom: 1pt; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">DESCRIPTION</TD></TR>
<TR>
    <TD STYLE="padding-top: 5pt; text-align: center; vertical-align: top">99.1</TD>
    <TD STYLE="padding-top: 5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-top: 5pt; vertical-align: top">CureVac N.V. Press Release dated September 29, 2020.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2031949d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>CureVac Initiates <FONT STYLE="color: #424242">Phase
2a Clinical Trial of COVID-19 Vaccine Candidate </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #424242"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Study conducted in Peru and Panama
</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Trial involves 690 participants, including
older adults</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #424242"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Evaluation of safety, reactogenicity
and immunogenicity</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white; color: #424242"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>T&Uuml;BINGEN, Germany/
BOSTON, USA &ndash; September 29, 2020</B> &ndash; CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing
a new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), announced today that the first
participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study,
entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distinct
groups: older adults ages 61 and above, and younger participants 18 to 60 years old.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">The participants will receive
two vaccinations at intervals of 28 days. Different dose levels will be investigated, starting at 6 &micro;g, with the aims to
confirm safety and evaluate reactogenicity of the vaccine in older adults. In addition, in a geographical environment with a high
incidence of COVID-19 infection, the humoral immune response after administration of CVnCoV will be assessed and the safety database
will be expanded to prepare for the start of a phase 2b/3 study. First comprehensive data of Phase 2a in older adults are expected
later in the fourth quarter 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">The study design was coordinated
with and approved by the health authorities and ethics committees of Peru and Panama and is based on preliminary safety and immunogenicity
data from CureVac's ongoing Phase 1 CV-NCOV-001 study in healthy adult volunteers in Germany and Belgium. Pending further data
from the ongoing Phase 1 and the Phase 2a study, CureVac plans to initiate the global Phase 2b/3 clinical trial enrolling approximately
30,000 participants in the fourth quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&quot;The start of the clinical
Phase 2a trial in Peru and Panama represents an important step forward in our COVID-19 clinical study program,&quot; Dr. Mariola
Fotin-Mleczek, Chief Technology Officer of CureVac, said. &quot;This trial is designed to further confirm the selection of the
dose of our vaccine candidate and to confirm that we can provide a safe and tolerable vaccine, also to older adults, who are at
a higher risk of experiencing serious impacts from COVID-19.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>About CVnCoV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac first began development
of its mRNA-based COVID-19 vaccine candidate in January 2020. After extensive preclinical development, the company began its Phase
1 clinical study of CVnCoV in June 2020 at clinical study centers in Germany and Belgium. The company has substantial production
capacities for mRNA vaccines at its headquarters in T&uuml;bingen and is currently expanding those manufacturing capacities to
allow for broad-scale manufacturing of CVnCoV and other mRNA-based vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>About CureVac</B><BR>
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in
developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the
use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the
treatment of rare diseases. CureVac is headquartered in T&uuml;bingen, Germany with sites in Frankfurt and Boston, USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>CureVac Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">Thorsten Sch&uuml;ller, Vice
President Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">T: +49 7071 9883-1577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="color: Blue"><U>thorsten.schueller@curevac.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>CureVac Investor Relations
Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">Dr. Sarah Fakih, Vice President
Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">T: +49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="color: Blue"><U>sarah.fakih@curevac.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>Contact for Latin American
Journalists<BR>
</B>Gloria Ni&ntilde;o de Rivera</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Face-to-Face Proyecci&oacute;n y Cuidado de Asuntos Corporativos,
S.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">01330 Ciudad de M&eacute;xico</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M&eacute;xico</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dir: +52 55 5292 3568 | Mobile: +521 55 5076 1524</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>glorianr@facetofacelatam.onmicrosoft.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>Forward-Looking Statements<BR>
</B><FONT STYLE="background-color: white">This press release contains statements that constitute &ldquo;forward looking statements&rdquo;
as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express
the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the &ldquo;company&rdquo;) regarding
future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the
company&rsquo;s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking
statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project<STRIKE>,</STRIKE>&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative
of these terms or similar expressions. Forward-looking statements are based on management&rsquo;s current beliefs and assumptions
and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company&rsquo;s
performance, and you should not place undue reliance on such statements.&nbsp; Forward-looking statements are subject to many risks,
uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility
in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical
trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability
to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition and consolidation in the company&rsquo;s industry, the effects
of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability to manage growth, reliance on key personnel,
reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due
to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s control and
could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included
in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events
or developments, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&rsquo;s
reports and documents filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC). You may get these documents by visiting
EDGAR on the&nbsp;SEC&nbsp;website at&nbsp;<FONT STYLE="color: Blue"><U>www.sec.gov</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ *\# 2(  A$! Q$!_\0
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MD\,&RACT70OB#J\E[:>,OB7II$:E-=\4:*;*QG1H$-K?WGB?6TN7OM>F-O\
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MB?XJZWX?\/>"9-7\&^%+_4?$Z(^C2ZU\0?&6A^ O!&CW$;V]S%)/XC\;^)-
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37]>U*_U?5+ZYO;J65O2J* /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
